Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer

Clin Colorectal Cancer. 2004 May;4(1):16. doi: 10.3816/ccc.2004.n.006.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Colorectal Neoplasms / blood supply
  • Colorectal Neoplasms / drug therapy*
  • Fluorouracil / administration & dosage
  • Humans
  • Neovascularization, Pathologic*
  • Randomized Controlled Trials as Topic
  • Receptors, Vascular Endothelial Growth Factor / drug effects
  • Receptors, Vascular Endothelial Growth Factor / physiology
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • Androgen Antagonists
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Fluorouracil